urea has been researched along with Anochlesia in 6 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| "ACP-103 also attenuated catalepsy produced by haloperidol or risperidone." | 1.34 | ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. ( Anderson, GT; Barido, R; Bonhaus, DW; Brann, MR; Brunmark, P; Davis, RE; Dyssegaard, A; Gardell, LR; Hacksell, U; Johnson, RW; Pounds, L; Tabatabaei, A; Vanover, KE; Veinbergs, I, 2007) |
| "Because catalepsy is thought to be a good predictor of extrapyramidal symptoms in humans, treatment with orexin-1 antagonists might decrease the occurrence or severity of antipsychotic treatment-emergent extrapyramidal symptoms in humans." | 1.34 | The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. ( Hemrick-Luecke, SK; Hsu, MA; Johnson, BG; Noone, S; Rasmussen, K; Thompson, LK, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumari, N | 1 |
| Agrawal, S | 1 |
| Luthra, PM | 1 |
| Azam, F | 2 |
| Alkskas, IA | 1 |
| Ahmed, MA | 1 |
| Prasad, MV | 1 |
| Thangavel, N | 1 |
| Shrivastava, AK | 1 |
| Mohan, G | 1 |
| Gardell, LR | 1 |
| Vanover, KE | 1 |
| Pounds, L | 1 |
| Johnson, RW | 1 |
| Barido, R | 1 |
| Anderson, GT | 1 |
| Veinbergs, I | 1 |
| Dyssegaard, A | 1 |
| Brunmark, P | 1 |
| Tabatabaei, A | 1 |
| Davis, RE | 1 |
| Brann, MR | 1 |
| Hacksell, U | 1 |
| Bonhaus, DW | 1 |
| Rasmussen, K | 1 |
| Hsu, MA | 1 |
| Noone, S | 1 |
| Johnson, BG | 1 |
| Thompson, LK | 1 |
| Hemrick-Luecke, SK | 1 |
| Pieri, M | 1 |
| Schaffner, R | 1 |
| Pieri, L | 1 |
| Da Prada, M | 1 |
| Haefely, W | 1 |
6 other studies available for urea and Anochlesia
| Article | Year |
|---|---|
Pharmacological assessments of potent A
Topics: Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Animals; Antiparkinson Agents; | 2017 |
Synthesis of some urea and thiourea derivatives of 3-phenyl/ethyl-2-thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidine and their antagonistic effects on haloperidol-induced catalepsy and oxidative stress in mice.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Brain; Catalepsy; Glutathione; Glutathione Pe | 2009 |
Structure-based design, synthesis and molecular modeling studies of thiazolyl urea derivatives as novel anti-parkinsonian agents.
Topics: Animals; Antiparkinson Agents; Catalepsy; Chemistry Techniques, Synthetic; Drug Design; Haloperidol; | 2012 |
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Brain Chemistry; Catalep | 2007 |
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Benzodiazepines; Benzoxazol | 2007 |
Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD.
Topics: 5,7-Dihydroxytryptamine; Animals; Apomorphine; Behavior, Animal; Brain Injuries; Catalepsy; Ergoline | 1978 |